Colonic Dilation and Altered Ex Vivo Gastrointestinal Motility in the Neuroligin-3 Knockout Mouse

Anita J. L. Leembruggen, Gayathri K. Balasuriya, Jinghong Zhang, Shana Schokman, Kristy Swiderski, Joel C. Bornstein, Jess Nithianantharajah, and Elisa L. Hill-Yardin

Gastrointestinal (GI) dysfunction is commonly reported by people diagnosed with autism spectrum disorder (ASD; autism) but the cause is unknown. Mutations in genes encoding synaptic proteins including Neuroligin-3 are associated with autism. Mice lacking Neuroligin-3 (Nlgn3−/−) have altered brain function, but whether the enteric nervous system (ENS) is altered remains unknown. We assessed for changes in GI structure and function in Nlgn3−/− mice. We found no significant morphological differences in villus height or crypt depth in the jejunum or colon between wildtype (WT) and Nlgn3−/− mice. To determine whether deletion of Nlgn3 affects enteric neurons, we stained for neural markers in the myenteric plexus. Nlgn3−/− mice had similar numbers of neurons expressing the pan-neuronal marker Hu in the jejunum, proximal mid, and distal colon regions. We also found no differences in the number of neuronal nitric oxide synthase (nNOS+) or calretinin (CalR+) motor neurons and interneurons between WT and Nlgn3−/− mice. We used ex vivo video imaging analysis to assess colonic motility under baseline conditions and observed faster colonic migrating motor complexes (CMMCs) and an increased colonic diameter in Nlgn3−/− mice, although CMMC frequency was unchanged. At baseline, CMMCs were faster in Nlgn3−/− mice compared to WT. Although the numbers of neuronal subsets are conserved in Nlgn3−/− mice, these findings suggest that Neuroligin-3 modulates inhibitory neural pathways in the ENS and may contribute to mechanisms underlying GI disorders in autism.

Lay Summary: People with autism commonly experience gut problems. Many gene mutations associated with autism affect neuronal activity. We studied mice in which the autism-associated Neuroligin-3 gene is deleted to determine whether this impacts gut neuronal numbers or motility. We found that although mutant mice had similar gut structure and numbers of neurons in all guts examined, they had distended colons and faster colonic muscle contractions. Further work is needed to understand how Neuroligin-3 affects neuron connectivity in the gastrointestinal tract.

Keywords: autism; gastrointestinal symptoms; gut motility; Neuroligin-3; mouse models; immunofluorescence

Introduction

Autism spectrum disorder (ASD; autism) is a highly prevalent neurodevelopmental disorder with current figures suggesting that 1 in 59 children are affected in the United States [Baio et al., 2018]. ASD is diagnosed based on impaired social interaction and communication, and restrictive and repetitive behaviors [APA DSM-5, 2013]. The prevalence of gastrointestinal (GI) disorders (e.g., acute constipation, diarrhea, and abdominal pain) is increased in patients with autism compared to the general population [Valicenti-McDermott et al., 2006]. Children diagnosed with autism are twice as likely to be prescribed medication for GI disorders and four times more likely to be hospitalized with GI disorders compared to neurotypical children [Croen, Najjar, Ray, Lotspeich, & Bernal, 2006; McElhanon, Mccracken, Karpen, & Sharp, 2014; Valicenti-McDermott et al., 2006]. A meta-analysis of 84 studies of GI dysfunction in autism patients identified a median prevalence of 22.2% for constipation, 13% for diarrhea, and 46.8% for any GI symptom [Holingue et al., 2018]. Additional studies have identified that 60–74% of children patients with autism experience inflammation of the small or large intestine [Horvath, Papadimitriou, Rabstyn, Drachenberg, & Tildon, 1999; Krigsman et al., 2010].

Autism has a strong genetic component, with monozygotic twins more likely to be diagnosed with autism compared to dizygotic twins [Bailey et al., 1995; Folstein & Rosen-Sheidley, 2001; Steffenburg et al., 1989]. Additionally,
in 10–20% of autism cases, rare genetic mutations that are thought to underlie the core symptoms are expressed [Betancur, 2011; Geschwind, 2011; Voineagu et al., 2011]. Of over 1,000 genes implicated in the development of autism [Basu, Kolli, & Banerjee-Basu, 2009], many are involved in nervous system development and synaptic transmission [Cristino et al., 2014]. Multiple mutations in proteins involved in neuronal communication are associated with autism, including in Neuruligin-3 (Nlgn3) and associated synaptic proteins [Alarcón et al., 2008; Arking et al., 2008; Bakkaloglu et al., 2008; Bourgeron, 2015; Comolli et al., 2004; Durand et al., 2007; Feyder et al., 2010; Jamain et al., 2003; Moessner et al., 2007; Phelan et al., 2001].

There has been little investigation into the effect of autism-associated mutations on the enteric nervous system (ENS), the intrinsic nervous system of the gut. The ENS comprises the submucosal plexus, which primarily regulates the secretion of water and electrolytes into the gut lumen, and the myenteric plexus (MP), which regulates the movement of food within the gut [reviewed in Furness, 2012].

Approximately 20–40% of neurons in the mouse MP are immunoreactive (IR) for neuronal nitric oxide synthase (nNOS; Sang & Young, 1996). Nitric oxide (NO) is an inhibitory neurotransmitter in the ENS and is expressed in inhibitory motor neurons, as well as a subset of descending (anally projecting) interneurons [Furness, 2000; Brookes, 1993; Brookes, 2001]. Other myenteric neurons express the calcium binding protein Calcitonin (CaR) including ascending (orally projecting) interneurons, and intrinsic sensory neurons. These neurons receive and relay information regarding distention, pH levels, and solute concentrations in the gut via signaling from enterochromaffin cells located in the gut epithelium [Furness, 2006; Surawicz, 2010] to motor and interneurons to coordinate gut function [Bertrand, Kunze, Bornstein, Furness, & Smith, 1997].

Genes encoding the neuruligin (NLGN) family of cell adhesion molecules are implicated in autism [Jamain et al., 2003], synaptogenesis [Shen, Huo, Zhao, Wang, & Zhong, 2015], and the maintenance of synaptic structural integrity via binding to various postsynaptic proteins such as PSD-95 [Sudhof, 2008]. Although mutations in Nlgn3 are rare, neuruligins are part of postsynaptic signaling complex within which many mutations cause autism [Betancur, Sakurai, & Buxbaum, 2009; reviewed in Bourgeron, 2009]. It is therefore of interest to characterize changes in GI structure and function caused by mutations in Nlgn3. A deletion of the Nlgn3 gene was observed in a male diagnosed with ASD [Levy et al., 2011] and in another case with pervasive developmental disorder not otherwise specified [Sanders et al., 2011]. A missense mutation in Nlgn3 causing the substitution of a conserved arginine for a cysteine residue at position 451 within the NLGN3 protein was identified in two brothers diagnosed with ASD [Jamain et al., 2003].

Mice null for Neuruligin-3 (Nlgn3−/−) have reduced vocalizations and social interaction [Jaramillo, Liu, Pettersen, Birnbaum, & Powell, 2014; Radyushkin et al., 2009], congruent with impaired social communication in autism. Nlgn3−/− mice also display altered neurophysiology in the brain. Specifically, Nlgn3−/− mice display a decreased frequency of miniature excitatory postsynaptic currents and an increased frequency of miniature inhibitory postsynaptic currents in the hippocampus [Etherton et al., 2011]. Nlgn3−/− mice also have increased GABAergic neurotransmission at cholecystokinin-immunoreactive basket cell synapses [Földy, Malenka, & Südhof, 2013], and impaired tonic cannabinoid signaling [Földy et al., 2013], further demonstrating altered synaptic function.

Here, we aimed to determine whether deletion of the Neuruligin-3 synaptic protein impacts GI structure or function by assessing for regional structural changes at the histological and cellular levels as well as examining ex vivo colonic motility.

Material and Methods

Animals

Nlgn3−/− mice were originally generated via homologous recombination of embryonic stem cells to induce deletion of at least 380 base pairs of S′ coding of the Nlgn3 gene [Varoqueaux et al., 2006] and subsequently bred onto C57Bl/6NCr mice for more than 10 generations [Radyushkin et al., 2009]. Nlgn3−/− mice and their respective WT littermate matched controls were generated by mating heterozygous females with WT males. Genotypes of male 12-week-old mice were verified by polymerase chain reaction and confirmed with Western blots of brain homogenates from homozygous Nlgn3−/− mice demonstrating a lack of full length NL3 or truncated variants in the Nlgn3−/− mice. Mice processed for immunofluorescent staining were anesthetized with 0.05 mL pentobarbitrate before transcardial perfusion with 4% paraformaldehyde (PFA) at a rate of 10 mL/min for 3 min. Animals used for video imaging experiments were killed via cervical dislocation, as approved by the Florey Institute Animal Ethics Committee (Ethics ID: 14-095).

Histology

To investigate the effects of Nlgn3 deletion on GI structure, transverse sections of the proximal jejunum and proximal colon were stained with hematoxylin and eosin. Sections of proximal jejunum and proximal colon from WT and Nlgn3−/− mice were dissected and placed in individual 1.5 mL Eppendorf tubes filled with 4% PFA to postfix at 4°C overnight. The tissue was rinsed three times in phosphate buffered saline (PBS) for 10 min and incubated in a 30% sucrose solution overnight at 4°C. The tissue sections were placed in optimal cutting temperature medium (Tissue Tek, Elkhart IN) and immediately snap frozen in iso-pentane cooled with liquid nitrogen. Frozen tissue preparations were cross-sectioned at 10-μm thickness using a cryostat (Microm HM 525, Fronine Laboratory...
Histological Parameters

Brightfield images of stained sections were obtained using a Zeiss Axio Imager D1 Microscope (Glaedsville, NSW, Australia), and analyzed for villus height and crypt depth using ImageJ/FIJI software (Version 1.49d, NIH). Only villi with the full lacteal visible were measured for villus height (the length between tip of the villus and the villus/crypt junction), with a minimum of 10 villi per animal measured in WT (n = 5) and Nlgn3\(^{-/-}\) (n = 5) mice from approximately 10 tissue sections. Crypt depth was measured as the length between the base of the crypt and the villus/crypt junction. Measurements were obtained from both the proximal jejunum and proximal colon. At least 10 crypts per animal were measured in WT and Nlgn3\(^{-/-}\) mice.

Immunofluorescence

To assess for changes in neuronal subpopulations, myenteric preparations were labeled for nNOS and CalR that together, label approximately 70–75% of myenteric neurons [Sang & Young, 1996]. The proximal jejunum and entire colon were dissected, opened along the mesenteric border and pinned in a petri dish lined with silicone elastomer (Sylgard 184, Dow Corning), before being postfixed overnight in 4% PFA at 4°C. Fixed tissue was rinsed three times at 10-min intervals in PBS (pH = 7.2). The mucosa, submucous plexus, and circular muscle were peeled away from the underlying MP. Longitudinal muscle myenteric plexus preparations were permeabilized in CASBLOCK +0.1% Triton for 30 min at RT, prior to incubation in primary antisera (Table 1) at 4°C for 24–48 hr. Each tissue preparation was rinsed in PBS three times at 10 min intervals before incubation with secondary antibodies (Table 2) for 2 hr at RT. Following an additional round of PBS rinses, the tissue preparations were mounted onto glass microscope slides in DAKO fluorescence mounting medium (DAKO, Carpinteria, CA) and secured with a glass coverslip. An Axio Imager2 fluorescence microscope was used to image 4–5 randomly selected areas per whole mount preparation. All images were exported as .tif files to preserve resolution and were adjusted for brightness and contrast using ImageJ/FIJI.

Cell Counts

To count neurons, the “Cell Counter” plugin on ImageJ/FIJI (Version 1.49d, NIH) was used. Neurons IR for Hu were manually counted in a single field of view (2,752 pixels \( \times \) 2,208 pixels; 625 \( \times \) 501 \( \mu \text{m}^2 \), total area of 0.3 \( \text{mm}^2 \)). All whole neurons and neurons intersecting the bottom and left borders of the image were counted; however, neurons intersecting the top and right borders of the image were not included. Counts were performed by two assessors blind to the genotype (WT or Nlgn3\(^{-/-}\)) of the tissue preparations. Cell count data, which was obtained as the number of neurons per 0.3 \( \text{mm}^2 \), were converted to the number of neurons per \( \text{mm}^2 \).

| Table 1. Primary Polyclonal Antisera Used for Immunohistochemistry |
|-----------------------------|-------------------|-----------------|-------------------|
| Primary antibody           | Host species      | Concentration   | Source            |
| Hu                          | Human            | 1:5,000         | Kind gift from Dr. V. Lennon |
| nNOS                        | Sheep            | 1:1,000         | Kind gift from Dr. P. Emson |
| Calretinin                  | Goat             | 1:1,000         | Swant (6G1)       |

Immunoprecipitation and Western Immunoblotting to Confirm Neuroligin-3 Expression in Colon

Snap frozen brain, proximal colon, and distal colon tissue from WT and Nlgn3\(^{-/-}\) mice were homogenized in lysis buffer [1% v/v Triton X-100, 50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 2 mM Na\(_3\)VO\(_4\), 50 mM NaF, and complete protease inhibitor cocktail (Roche Applied Science)]. Lysates were cleared by centrifugation at 20,000g for 10 min at 4°C and incubated 2 hr at 4°C on rotating wheel with 50 \( \mu \text{g} \) protein A sepharose 4B (PAS; Thermo Fisher Scientific; Waltham, MA). Cleared lysates (100 \( \mu \text{g} \) for brain, 2.5 mg for colon) were subject to immunoprecipitation with an antibody directed to Neuroligin-3 (3 \( \mu \text{g} \) per sample, Rabbit-\( \alpha \)-Neuroligin 3; Synaptic systems Cat #129113) at 4°C overnight (o/n) and immune complexes were captured the next day with PAS for 2 hr at 4°C. Beads were washed three times with high salt lysis buffer [1% v/v Triton X-100, 50 mM Tris–HCl pH 7.5, 300 mM NaCl, 1 mM EDTA, 2 mM Na\(_3\)VO\(_4\), 50 mM NaF, and complete protease inhibitor cocktail (Roche Applied Science)] and immunocaptured proteins were eluted by incubation for 5 min at 95°C. Eluted proteins were separated by SDS-PAGE alongside a molecular weight marker (Precision Plus Protein™ all blue prestained protein standard, Bio-Rad Laboratories, Hercules, CA) on a 4–12% gradient mini-PROTEAN TGX pre-cast gel (Bio-Rad Laboratories), and transferred to polyvinylidene difluoride (PVDF) membrane by semi-dry transfer on a Trans-blot turbo (Bio-Rad Laboratories). Membranes were blocked in 5% bovine serum albumin (BSA)/tris-buffered saline with 0.1% Table 2. Secondary Polyclonal Antisera Used for Immunohistochemistry

| Secondary antibody | Host species | Concentration | Source            |
|--------------------|--------------|---------------|-------------------|
| Human Alexa 594    | Donkey       | 1:5,000       | Molecular probes (A11001) |
| Human Alexa 647    | Donkey       | 1:500         | Jackson (709-605-169) |
| Sheep Alexa 488    | Donkey       | 1:400         | Molecular probes (A11015) |
tween-20 (TBST) for 1 hr at RT and incubated o/n at 4°C with the antibody directed to Neuroligin-3 (1:1,000 in 5% BSA/TBST). Membranes were washed 4x with TBST, incubated 1 hr at RT with horseradish peroxidase-conjugated donkey antirabbit immunoglobulin (1:5,000 in 5% BSA/TBST; GE Healthcare Life Sciences; Marlborough, MA), washed 4x with TBST and developed by enhanced chemiluminescence (ECL Prime; GE Healthcare Life Sciences) on a ChemiDoc MP Imaging System (Bio-Rad Laboratories).

**Video Imaging**

Colonic motility was recorded ex vivo using a Logitech camera (QuickCam Pro 4000; I-Tech, Ultimo, NSW, Australia) mounted directly above an organ bath as previously described [Balasuriya, Hill-Yardin, Gershon, & Bornstein, 2016; Swaminathan et al., 2016]. Experiments consisted of control, drug, and drug washout recordings (each consisting of four segments of 15 min recordings). The nNOS inhibitor No-nitro-l-arginine (NOLA) was applied to the organ bath and resulting contractions were compared between Nlgn3+/− mice and their WT littermates. Using the in-house software Scribble 2.0 and the Matlab (2013b) plugin Analyse 2.0, recorded videos were converted to spatiotemporal maps reflecting the diameter of the colon along the length of the tissue (y-axis) as a function of time (x-axis). A color bar indicated luminal diameter, where pixels with cool colors (e.g., blue-green) indicated dilated tissue, whereas pixels with warmer colors (e.g., yellow-red) indicated a constricted colon. CMMCs originating at the oral end of the colon and propagating more than half of the length of the tissue were included for analysis. Recordings were analyzed for the number of CMMCs, CMMC speed, and resting colonic diameter, as described by Swaminathan et al. [2016] and Balasuriya et al. [2016]. Briefly, CMMC frequency was manually counted from spatiotemporal maps and resting gut diameter (the diameter of the relaxed colon in between CMMCs) was derived from a data point in spatiotemporal maps at two-thirds of the colonic length from the oral end.

**Statistical Analysis**

Statistical analysis was performed using Graphpad Prism (Version 7.05, CA). Villus height, crypt depth, and cell count data were analyzed using two-tailed, unpaired t tests and one-way ANOVA. CMMC speed and resting gut diameter data were analyzed using a Student’s t test with Bonferroni correction for multiple comparisons. CMMC numbers were analyzed using a Mann–Whitney test. Data are presented as mean ± SEM.

**Results**

To establish whether deletion of Neuroligin-3 affects gut structure and function, we assessed colonic crypt depth, jejunal crypt depth and villus height, neuronal subpopulations, and colonic motility in the GI tract of WT and Nlgn3+/− mice.

There were no obvious differences in the major morphological features of the jejunum between WT and Nlgn3+/− mice. Both WT and Nlgn3+/− mice had typical jejunal morphology, with no visible structural damage evident at the villus tips (Fig. 1A). WT and Nlgn3+/− mouse colon tissue structure was also similar (Fig. 1B). Additionally, there was no difference in villus height between WT and Nlgn3+/− mice (WT: 244 ± 11 μm, n = 5; Nlgn3+/−: 249 ± 8 μm, n = 5, P = 0.73 Fig. 1C). Crypt depth in the jejunum (WT: 37 ± 1 μm, n = 5; Nlgn3+/−: 39 ± 1 μm, n = 5, P = 0.33) and colon (WT: 47 ± 3 μm, n = 5; Nlgn3+/−: 42 ± 2 μm, n = 5, P = 0.22) were also unchanged in Nlgn3+/− mice (Fig. 1D) suggesting that the absence of Neuroligin-3 produces no overt changes in mucosal structure in these regions. There were no overt signs of GI abnormality in mice lacking Nlgn3 upon removing the colon from the animal.

To determine if neuronal number is altered in Nlgn3+/− mice, we labeled myenteric neurons for the pan-neuronal marker, Hu. We observed a significant effect of gut region (P < 0.0001) whereby the highest numbers of neurons were found in the proximal colon, followed by the mid and distal colon, with the lowest number of neurons present in the proximal jejunum. However, there was no genotype difference in the total number of neurons in any region (Fig. 2A–C, P = 0.44 (genotype, two-way ANOVA)). The total number of Hu + neurons per mm² in the proximal jejunum (WT: 228 ± 8, n = 5; Nlgn3+/−: 238 ± 22, n = 5), proximal colon (WT: 723 ± 104, n = 5; Nlgn3+/−: 638 ± 35, n = 5), mid colon (WT: 597 ± 34, n = 5; Nlgn3+/−: 721 ± 30, n = 9), or distal colon (WT: 390 ± 26, n = 8; Nlgn3+/−: 432 ± 30, n = 9) were similar in WT and Nlgn3+/− mice.

We also investigated whether the number of nNOS+ neurons and CalR+ neurons were altered in Nlgn3+/− and WT mice. As for the total number of neurons, the number of nNOS+ neurons per mm² was similar for both genotypes (P = 0.09, two-way ANOVA) and showed a significant difference between regions, with the lowest numbers of nNOS+ neurons in the proximal jejunum (P < 0.0001, two-way ANOVA, Fig. 2A, D). NOS+ neuronal numbers in the proximal jejunum of Nlgn3+/− mice were unchanged compared to WT (WT: 56 ± 2, n = 5; Nlgn3+/−: 67 ± 5, n = 5). Similarly, there was no difference in the number of nNOS+ neurons in the proximal colon (WT: 161 ± 24, n = 5; Nlgn3+/−: 189 ± 21, n = 5), mid colon (WT: 144 ± 33, n = 5; Nlgn3+/−: 180 ± 30, n = 5), or distal colon (WT: 39 ± 10, n = 5; Nlgn3+/−: 178 ± 19, n = 5). The number of CalR+ neurons was also similar in the proximal jejunum (WT: 29 ± 1.7, n = 5; Nlgn3+/−: 28 ± 3, n = 5), proximal colon (WT: 65 ± 11, n = 4; Nlgn3+/−: 46 ± 2, n = 3), mid colon (WT: 131 ± 22, n = 5; Nlgn3+/−: 158 ± 19, n = 8), and distal colon (WT: 39 ± 10, n = 6; Nlgn3+/−: 40 ± 3, n = 7) of WT and Nlgn3+/− mice (P = 0.62, two-way ANOVA; Fig. 2B, E).
was a significant difference in the number of CalR+ neurons observed between the gut regions, with the lowest numbers found in the proximal jejunum ($P = 0.006$, two-way ANOVA). These findings indicate that the deletion of Nlgn3 does not affect the total number of myenteric neurons or the numbers of nNOS or CalR IR neurons in the mouse proximal jejunum or colon MP.

We then assessed for potential alterations to proportions of motor neurons or interneurons in Nlgn3$^{-/-}$ mice by labeling MP preparations for nNOS and CalR and calculating the mean proportion of each of these markers as a percentage of the total neuronal population (IR for Hu). Although we observed a significant difference in the proportion of nNOS+ neurons between gut regions in both genotypes, whereby the distal colon had the highest proportion of nNOS+ neurons ($P = 0.001$, two-way ANOVA), there was no difference in the proportion of nNOS+ neurons between WT and Nlgn3$^{-/-}$ mice (Fig. 2, $P = 0.34$, two-way ANOVA). We observed no significant difference in the proportion of nNOS+ neurons between WT and Nlgn3$^{-/-}$ mice in the proximal jejunum (WT: 26 ± 1%, $n = 5$; Nlgn3$^{-/-}$: 27 ± 0.8%, $n = 5$), proximal colon (WT: 26 ± 2%, $n = 5$; Nlgn3$^{-/-}$: 30 ± 3%, $n = 5$), mid colon (WT: 25 ± 5%, $n = 5$; Nlgn3$^{-/-}$: 29 ± 3%, $n = 5$), or distal colon (WT: 40 ± 2.5%, $n = 5$; Nlgn3$^{-/-}$: 40 ± 7%, $n = 5$). Additionally, similar proportions of CalR+ neurons were present in the proximal jejunum (WT: 40 ± 2%, $n = 5$; Nlgn3$^{-/-}$: 40 ± 4%, $n = 5$), proximal colon (WT: 34 ± 7%, $n = 5$; Nlgn3$^{-/-}$: 36 ± 11, $n = 4$), mid colon (WT: 24 ± 3%, $n = 5$; Nlgn3$^{-/-}$: 21 ± 3%, $n = 8$), and distal colon (WT: 32 ± 6%, $n = 6$; Nlgn3$^{-/-}$: 32 ± 4%, $n = 7$) in WT and Nlgn3$^{-/-}$ mice ($P = 0.67$, two-way ANOVA, Fig. 2).

Neuroligin-3 protein expression was assessed using immunoprecipitation and Western blot in brain, proximal colon, and distal colon of WT and Nlgn3$^{-/-}$ tissue (Fig. 3). Neuroligin-3 migrated at approximately 100 kDa in WT tissue as previously reported [Varoqueaux et al., 2006]. This band was absent in all Nlgn3$^{-/-}$-derived samples.

To determine if NL3 deletion affects gut diameter and contractility in the absence of input from the central nervous system, we undertook ex vivo video imaging analysis of colon diameter and spontaneous CMMCs as previously reported [Swaminathan et al., 2016] in WT and Nlgn3$^{-/-}$ mice. Nlgn3$^{-/-}$ mice had increased resting colonic diameters compared to WT mice under control conditions (WT: 3.4 ± 0.2 mm, $n = 16$; Nlgn3$^{-/-}$: 4.0 ± 0.1 mm, $n = 15$, $P = 0.03$, Figure 1.

Comparison of GI morphology in WT and Nlgn3$^{-/-}$ mice. Sections of Nlgn3$^{-/-}$ and WT jejunum (A), and colon (B) stained with Hematoxylin and Eosin. There was no difference in villus height in the jejunum (C) between WT and Nlgn3$^{-/-}$ mice ($n = 5$ in each group), or crypt depth in the jejunum or colon (D) in either genotype ($n = 5$ in each group). Scale bars = 50 μm. Statistics: Student’s $t$ test. Villus height and crypt depth were measured as indicated by the broken lines in the left panel of A.
Fig. 4A–C). However, there was no significant difference in the number of CMMCs between WT and Nlgn3−/− mice (WT: 8.4 ± 1 CMMCs/15 min, n = 19; Nlgn3−/−: 9.4 ± 1 CMMCs/15 min, n = 16, P = 0.34, Fig. 4D). Interestingly, Nlgn3−/− mice showed significantly faster CMMC speeds compared to WT mice (WT: 1.8 ± 0.1 mm/s, n = 15; Nlgn3−/−: 2.4 ± 0.2 mm/s, n = 17, P = 0.04, Fig. 4A, B, and E).

To assay for differential effects of NO in WT and Nlgn3−/− mice, resting colon diameter and number and speed of CMMCs were assessed in the presence of NOLA, an inhibitor of nitric oxide synthase (NOS). It is well established that NOLA increases CMMC frequency [Powell & Bywater, 2001; Roberts et al., 2007]. To determine the magnitude of the effect of NOLA on the colon, we calculated the percentage change in motility parameters between NOLA and baseline conditions. In the presence of NOLA, both Nlgn3−/− and WT mice showed a similar percentage decrease in gut width compared to baseline (WT: 23 ± 3%, n = 16; Nlgn3−/−: 20 ± 4%, n = 14, P = 0.52, Fig. 5A–C; raw values: WT: 2.6 ± 0.2 mm, n = 15; Nlgn3−/−: 3.2 ± 0.2 mm, n = 18). CMMC frequency in NOLA was also similar in WT and Nlgn3−/− mice (WT: 32 ± 12% CMMCs/15 min, n = 18; Nlgn3−/−: 41 ± 15% CMMCs/15 min, n = 15, P = 0.64, Fig. 5D; raw values: WT: 10.1 ± 0.5 CMMCs/15 min, n = 15; Nlgn3−/−: 11.6 ± 0.7 CMMCs/15 min, n = 18). However, Nlgn3−/− mice showed reduced sensitivity to NOLA as demonstrated by a smaller increase in CMMC speed in the presence of NOLA compared to WT mice (WT: 3.92 ± 0.24 mm/s, n = 15; Nlgn3−/−: 3.36 ± 0.29 mm/s, n = 18).

**Discussion**

This study aimed to determine the role of the synaptic adhesion molecule Neuroligin-3 in the structure and function of the GI tract by analyzing mucosal epithelial structure, the
neurochemistry of myenteric neurons and colonic motility in the Nlgn3\(^{-/-}\) mouse model of autism. We reveal that Nlgn3\(^{-/-}\) mice have similar mucosal structure in the small and large intestine, and no change in myenteric neuronal numbers in the proximal jejunum or colon compared to WT mice. Nlgn3\(^{-/-}\) mice show both decreased colonic smooth muscle tone and altered colonic motility. Specifically, Nlgn3\(^{-/-}\) mice have an increased colonic diameter and faster CMMCs under baseline conditions. In the presence of the nNOS inhibitor NOLA, Nlgn3\(^{-/-}\) mice showed a smaller increase in CMMCs compared to WT mice.

Changes in GI tract mucosal morphology are reported in both the clinical setting and in animal models of autism, therefore we assessed for similar changes in Nlgn3\(^{-/-}\) mice. For example, partial villus atrophy [Horvath et al., 1999], cryptitis, and crypt branching [Krigsman et al., 2010] have been documented in patients with autism. Mice with modified serotonin reuptake transporter (SERT) function due to the autism-associated rare coding variant Ala56 (G56A) showed reduced villus height and crypt depth [Margolis et al., 2016]. Mice lacking SERT (SERT KO) showed increased villus height and crypt depth. In contrast, with these findings in the clinic and in other animal models of autism, Nlgn3\(^{-/-}\) mice jejunal and colon villus height and crypt depth were unaltered suggesting that Nlgn3 deletion does not overtly disrupt development and maintenance of the mucosal epithelium.

We observed similar neuronal numbers in the proximal jejunum and proximal, mid and distal colon of Nlgn3\(^{-/-}\) mice, suggesting that Nlgn3\(^{-/-}\) mice do not exhibit a major morphological phenotype in the MP of these regions of the GI tract. In contrast, myenteric neurons are decreased in the colon of SERT G56A mice, whereas SERT KO mice showed increased numbers of colonic myenteric neurons [Margolis et al., 2016]. There were also no changes in the number of cells immunofluorescent for the two neuronal markers examined (i.e., NOS and CalR). Although neither the overall number of neurons nor the numbers of two subtypes of neurons were altered, the Nlgn3 deletion may potentially impact GI function via modifying synaptic (i.e., varicosity) densities. Further work using high-resolution microscopy techniques to assess for such changes is required in these mice.

Here we show evidence for a subtle GI dysfunction phenotype in Nlgn3\(^{-/-}\) mouse colon. Using an ex vivo assay for motility enables ENS function to be assessed in the absence of input from the brain. We propose that the deletion of Nlgn3 reduced colonic smooth muscle tone leading to an increased resting colonic diameter, likely due to altered innervation of the smooth muscle. Other biological mechanisms potentially underlying this change in diameter could involve a change in the function of interstitial cells of Cajal that are involved in regulating the “pacemaker” activity of enteric myenteric neurons. Alternatively, differences in the levels of NO production could be present despite our observation that nNOS cell numbers are unchanged. Neuronal NO is a prominent inhibitory neurotransmitter synthesized by myenteric inhibitory motor neurons and interneurons [Sang & Young, 1996] that regulates smooth muscle relaxation between CMMCs [Brookes, 1993, Spencer, 2001]. Interestingly, under baseline conditions Nlgn3\(^{-/-}\) mice showed significantly faster CMMCs compared to WT colons. Although NOLA further increased CMMC speed in both genotypes, unsurprisingly, we observed a larger percentage change in WT than in Nlgn3\(^{-/-}\) mice given that WT had slower CMMCs at baseline. In light of our findings indicating no change in nNOS+ neuron numbers, the increased CMMC speed in Nlgn3\(^{-/-}\) mice could be due to altered expression of nNOS in circular smooth muscle cells [Grider et al., 1992], aberrant innervation of GI smooth muscle by nNOS neurons, or increased numbers of nNOS+ varicosities, which may cause an increase in NO in the ENS. The persistence of this fast CMMC phenotype in the presence of the NOS inhibitor NOLA suggests that it is not solely due to NO-mediated relaxation. There have been important advances in the understanding of the neuronal mechanisms underlying CMMCs in mice, such that each event involves coordinated neuronal firing of large populations of myenteric neurons [Spencer et al., 2018; Spencer, Dinning, Brookes, & Costa, 2016]. Although the numbers of myenteric neurons were not overtly different between the WT and Nlgn\(^{-/-}\) mice, it is possible that there are differences in synaptic activation of the interneurons that underlie CMMC generation, which could contribute to the differences detected.

The subtle nature of the GI tract changes in Nlgn3\(^{-/-}\) mice could be due to compensatory mechanisms occurring at...
the synaptic level. Neuroligin-3 forms heterodimers with Neuroligin-1 [Poulopoulos et al., 2012], which is found exclusively at excitatory synapses in the brain [Levinson et al., 2005]. Nlgn3−/− mice show decreased Neuroligin-1 levels in the forebrain [Tabuchi et al., 2007]; additionally, Nlgn1/Nlgn3 double knockout mice have a more severe phenotype compared to Nlgn3−/− mice [Varoqueaux et al., 2006]. Nlgn3 may play much larger roles in CMMC properties than detected in the current study if Nlgn3 was acutely obliterated using an inducible genetic deletion model, rather than double constitutive knockouts from birth (due to the compensatory mechanisms occurring in the physiological environment in knockouts from birth). However, the current constitutive deletion model is relevant for clinical studies where the gene deletion is present throughout life. The background strain of these mice may also influence the severity of the GI phenotype as has been shown for other models expressing autism-associated mutations in Nlgn3 [Jaramillo et al., 2018]. Additional studies investigating potential changes to the GI tract of Nlgn1/Nlgn3 double knockout mice, as well as Nlgn1−/− mice on different background strains, would allow a more comprehensive understanding

Figure 4. Baseline measurements of resting colon diameter and numbers of colonic migrating motor complexes (CMMCs) between WT and Nlgn3−/− mice. (A, B) Spatiotemporal maps showing baseline CMMCs in WT (A) and Nlgn3−/− (B) mice. (C) Resting gut diameter was higher in Nlgn3−/− mice (n = 16) compared to WT mice (n = 15, P = 0.03). (D) No difference in the number of CMMCs/15 min was observed between WT mice (n = 16) and Nlgn3−/− (n = 19, P = 0.38). (E) Nlgn3−/− mice (n = 17) had increased speed of CMMCs compared to WT mice (n = 15, P = 0.04). Statistics: Student's t test, Bonferroni post hoc test, Number of CMMCs assessed via Mann–Whitney test, *P < 0.05. Horizontal scale bar = Time (1 min). Vertical scale bar = 0.5 cm (length of colon). The color scale on the right of each map indicates the width of the gut for each captured frame during the 15-min recording. Arrows indicate individual CMMCs. The broken lines within the enlarged regions of the spatiotemporal maps in A and B highlight the gradient (speed) of the CMMCs.
of the roles of Neurolign-1 and Neuroligin-3 in GI structure and function.

Our findings support an emerging theme of altered GI function in genetic models of autism that has relevance for understanding GI dysfunction in individuals with neurodevelopmental disorders. A recent study of SERT G56A mice revealed both functional changes as well as decreased numbers of neurons in the MP, and decreased villus height and crypt depth in the GI tract [Margolis et al., 2016]. SERT G56A mice also exhibited decreased colonic motility [Margolis et al., 2016]. Other models of autism including mice and zebrafish heterozygous for the chromatin-remodeling gene CHD8 also display altered GI function in addition to changes in anatomical structure and neuronal numbers [Bernier et al., 2014; Katayama et al., 2016]. Emerging evidence that autism-associated mutations impact the ENS provides opportunities for application of extracerebral functional assays and preclinical therapy design in animal models. In summary, our findings indicate that an autism-associated mutation in Neuroligin-3 results in GI dysfunction and highlights a need for detailed characterization of ENS function in animal models of autism.

Acknowledgments

This work was supported by Australian Research Council Future Fellowship (FT160100126) to E.L.H.-Y. and National Health and Medical Research Council Project Grant (APP1083334) and Australian Research Council Future Fellowship (FT140101327) to J.N. E.L.H.-Y. also received an RMIT Vice Chancellor’s Senior Research Fellowship, which supported G.K.B. The Hu antibody was a gift from Dr. V. Lennon, Mayo Clinic, USA.

Conflict of Interest

The authors declare that there is no conflict of interest.

References

Alarcón, M., Abrahams, B. S., Stone, J. L., Duvall, J. A., Perederiy, J. V., Bomar, J. M., ... Nelson, S. F. (2008). Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. The American Journal of Human Genetics, 82(1), 150–159.
Jaramillo, T. C., Liu, S., Pettersen, A., Birnbaum, S. G., & Powell, C. M. (2014). Autism-related neuroligin-3 mutation alters social behavior and spatial learning. Autism Research, 7(2), 264–272.

Katayama, Y., Nishiyama, M., Shoji, H., Ohkawa, Y., Kawamura, A., Sato, T., ... Nakayama, K. I. (2016). CHD8 haploinsufficiency results in autistic-like phenotypes in mice. Nature, 537(7622), 675–679.

Krigman, A., Boris, M., Goldblatt, A., & Stott, C. (2010). Clinical presentation and histologic findings at ileocolonoscopy in children with autistic spectrum disorder and chronic gastrointestinal symptoms. Autism Insights, 2010(2), 1–11.

Levinson, J. N., Chéry, N., Huang, K., Wong, T. P., Gerrow, K., Kang, R., ... El-Husseini, A. (2005). Neuroligins mediate excitatory and inhibitory synapse formation: Involvement of PSD95 and neurexin-1Î± in neuroligin-induced synaptic specificity. Journal of Biological Chemistry, 280(17), 17312–17319.

Levy, D., Ronemus, M., Yamrom, B., Lee, Y. H., Leotta, A., Kendall, Margolis, K. G., Li, Z., Stevanovic, K., Saurman, V., Israelyan, N., Radyushkin, K., Hammerschmidt, K., Boretius, S., Varoqueaux, F., Roberts, R. R., Murphy, J. F., Young, H. M., & Bornstein, J. C. (2014). Autism-related neuroligin-3 mutation alters gastrointestinal and inhibitory synapse formation: Involvement of PSD95 and neurexin-1Î± in neuroligin-induced synaptic specificity. Journal of Biological Chemistry, 280(17), 17312–17319.

Levy, D., Ronemus, M., Yamrom, B., Lee, Y. H., Leotta, A., Kendall, J., ... Buja, A. (2011). Rare de novo and transmitted copy-number variation in autistic spectrum disorders. Neuron, 70(5), 886–897.

Margolis, K. G., Li, Z., Stevanovic, K., Saurnan, V., Israelyan, N., Anderson, G. M., ... Gershon, M. D. (2016). Serotonin transporter variant drives preventable gastrointestinal abnormalities in development and function. The Journal of Clinical Investigation, 126, 2221–2235.

McElhanon, B. O., McCracken, C., Karpen, S., & Stott, C. W. (2014). Gastrointestinal symptoms in autism spectrum disorder: A meta-analysis. Pediatrics, 133, 872–883.

Moessner, R., Marshall, C. R., Sutcliffe, J. S., Skaug, J., Pinto, D., Vincent, J., ... Scherer, S. W. (2007). Contribution of Shank3 mutations to autism spectrum disorder. American Journal of Human Genetics, 81, 1289–1297.

Phelan, M. C., Rogers, R. C., Saul, R. A., Stapleton, G. A., Sweet, K., Mcdermid, H., ... Kelly, D. P. (2011). 22q13 deletion syndrome. American Journal of Medical Genetics, 101, 91–99.

Poulouopoulos, A., Soykan, T., Tuffy, L. P., Hammer, M., Varoqueaux, F., & Brose, N. (2012). Homodimerization and isoform-specific heterodimerization of neuroligins. Biochemical Journal, 446(2), 321–330.

Powell, A. K., & Bywater, R. A. R. (2001). Endogenous nitric oxide release modulates the direction and frequency of colonic migrating motor complexes in the isolated mouse colon. Neurourogenentology & Motility, 13(3), 221–228.

Radyushkin, K., Hammerschmidt, K., Borelius, S., Varoqueaux, F., El-Kordi, A., Ronnenberg, A., ... Brose, N. (2009). Neuroligin-3-deficient mice: Model of a monogenic heritable form of autism with an olfactory deficit. Genes, Brain and Behavior, 8, 416–425.

Roberts, R. R., Murphy, J. F., Young, H. M., & Bornstein, J. C. (2007). Development of colonic motility in the neonatal mouse-studies using spatiotemporal maps. American Journal of Physiology-Gastrointestinal and Liver Physiology, 292(3), G930–G938.

Sanders, S. J., Ercan-Sencicek, A. G., Hus, V., Luo, R., Murtha, M. T., Moreno-De-Luca, D., ... Mason, C. E. (2011). Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron, 70(5), 863–885.

Sang, Q., & Young, H. M. (1996). Chemical coding of neurons in the myenteric plexus and external muscle of the small and large intestine of the mouse. Cell and Tissue Research, 284, 39–53.

Shen, C., Hsu, L.-R., Zhao, X.-L., Wang, P.-R., & Zhong, N. (2015). Novel interactive partners of neuroligin 3: New aspects for pathogenesis of autism. Journal of Molecular Neuroscience, 56, 89–101.

Spencer, N. J. (2001). Control of migrating motor activity in the colon. Current Opinion in Pharmacology, 1(6), 604–610.

Spencer, N. J., Dinning, P. G., Brookes, S. J., & Costa, M. (2016). Insights into the mechanisms underlying colonic motor patterns. Journal of Physiology, 594(15), 4099–4116.

Spencer, N. J., Hibberd, T. J., Travis, L., Wiklandt, L., Costa, M., Hu, H., ... Sorensen, J. (2018). Identification of a rhythmic firing pattern in the enteric nervous system that generates rhythmic electrical activity in smooth muscle. The Journal of Neuroscience, 38(24), 5507–5522.

Steffenburg, S., Gillberg, C., Hellgren, L., Andersson, L., Gillberg, C., Jakobsson, G., & Bohman, M. (1989). A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. Journal of Child Psychology and Psychiatry, 30, 405–416.

Sudhof, T. C. (2008). Neuroligins and neurexins link synaptic function to cognitive disease. Nature, 455, 903–911.

Swariciz, C. M. (2010). Mechanisms of diarrhea. Current Gastroenterology Reports, 12, 236–241.

Swaminathan, M., Hill-Yardin, E., Ellis, M., Zygorodimos, M., Johnston, L. A., Gwynne, R. M., & Bornstein, J. C. (2016). Video imaging and spatiotemporal maps to analyze gastrointestinal motility in mice. Journal of Visualized Experiments, 108, 53828.

Tabuchi, K., Blundell, J., Etherton, M. R., Hammer, R. E., Liu, X., Powell, C. M., & Sudhof, T. C. (2007). A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science, 318, 71–76.

Valicenti-Mcdermott, M., Mcvicar, K., Rapin, I., Wershil, B. K., Cohen, H., & Shinnar, S. (2006). Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. Journal of Developmental & Behavioral Pediatrics, 27, S128–S136.

Varoqueaux, F., Aramuni, G., Rawson, R. L., Mohrmann, R., Missler, M., Gottmann, K., ... Brose, N. (2006). Neuroligins determine synapse maturation and function. Neuron, 51, 741–754.

Voineagu, I., Wang, X., Johnston, P., Lowe, J. K., Tian, Y., Horvath, S., ... Geschwind, D. H. (2011). Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature, 474, 380–384.
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Leembruggen, AJL; Balasuriya, GK; Zhang, J; Schokman, S; Swiderski, K; Bornstein, JC; Nithianantharajah, J; Hill-Yardin, EL

Title:
Colonic dilation and altered ex vivo gastrointestinal motility in the neuroligin-3 knockout mouse

Date:
2020-05-01

Citation:
Leembruggen, A. J. L., Balasuriya, G. K., Zhang, J., Schokman, S., Swiderski, K., Bornstein, J. C., Nithianantharajah, J. & Hill-Yardin, E. L. (2020). Colonic dilation and altered ex vivo gastrointestinal motility in the neuroligin-3 knockout mouse. AUTISM RESEARCH, 13 (5), pp.691-701. https://doi.org/10.1002/aur.2109.

Persistent Link:
http://hdl.handle.net/11343/247428

File Description:
published version

License:
CC BY-NC